Novartis Acquires Kedalion Therapeutics
East Hanover, N.J., June 30, 2022 — Novartis today announced that it has acquired Kedalion Therapeutics and its AcuStream™ technology, an innovative device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. The acquisition enhances the Novartis ophthalmics portfolio,…Read More
Read MoreMerck Announces Launch of Merck Digital Sciences Studio
RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development. MDSS will support early-stage biomedical startups with direct investment, access to powerful…Read More
Read MoreAntheia Announces $40M in Debt Financing and Plans to Construct Pilot Plant Facility for Biomanufacturing
MENLO PARK, Calif., June 22, 2022 /PRNewswire/ — Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, today announced $40 million in venture debt financing from Oxford Finance LLC and Silicon Valley Bank, alongside plans to construct a new pilot scale biomanufacturing facility. The financing will support Antheia’s expansion with a 14,700 square-foot…Read More
Read MoreDigiLens Completes Second Close of Its Series D $50M Funding
Sunnyvale, CA – April 7, 2022: DigiLens Inc., an innovator in head worn holographic display and waveguide technology, today announced that Corning Incorporated has joined its Series D funding round as an investor. FLG partner Eric Mersch assisted. Corning joins a diverse and impressive list of investors in this round that…Read More
Read MoreSoleno Therapeutics Raises $15M in Under Written Public Offering
REDWOOD CITY, Calif., April 01, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the closing of an underwritten public offering of 40,000,000 shares of its common stock at a public offering price of…Read More
Read More